Science Translational Medicine Article Shows Galera’s Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors
12 mai 2021 16h01 HE
|
Galera Therapeutics
Describes mechanism which sensitizes cancer cells to radiotherapy Supports recent results showing a near doubling of median overall survival observed in patients with pancreatic cancer by combining...
Galera Reports First Quarter 2021 Financial Results and Recent Accomplishments
11 mai 2021 07h00 HE
|
Galera Therapeutics
Phase 3 ROMAN trial in severe oral mucositis expected to complete enrollment in 1H21; topline data expected in 2H21 Recently announced near doubling of median overall survival observed in...
Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference
05 mai 2021 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer
28 avr. 2021 16h01 HE
|
Galera Therapeutics
Near double the median overall survival observed in patients receiving Galera’s dismutase mimetic + SBRT versus placebo + SBRT, showing strong therapeutic potential Improvements versus placebo also...
Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Accomplishments
11 mars 2021 07h00 HE
|
Galera Therapeutics
Pivotal Phase 3 ROMAN Trial in Severe Oral Mucositis on Track for Completion of Enrollment in 1H21; Topline Data Readout in 2H21 Anticipate Final Data Readout from Locally Advanced Pancreatic...
Galera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
10 mars 2021 08h00 HE
|
Galera Therapeutics
MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
20 nov. 2020 08h00 HE
|
Galera Therapeutics
MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
10 nov. 2020 07h00 HE
|
Galera Therapeutics
Presented Promising Interim Data from Placebo-controlled Pilot Dismutase Mimetic SBRT Combination Trial for Pancreatic Cancer Announced Planned Phase 2b GC4711 SBRT Combination Trial for Pancreatic...
Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
03 nov. 2020 08h00 HE
|
Galera Therapeutics
MALVERN, Pa., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer
27 oct. 2020 15h00 HE
|
Galera Therapeutics
Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual Meeting First trial to evaluate anti-cancer activity...